Citations

Clear

13603 citation(s) found for "_, _".

Bilateral Kienböck Disease: Associations With Demographic, Systemic, and Radiologic Findings
Emanuels, Andrew, Rames, Jess D. , Tunaboylu, Mehmet Furkan , Moran, Steve, Emanuels, Andrew F., Rames, Jess, Moran, Steven L

Mayo Clinic

HAND | July 8, 2025 | Volume: 21 | Issue: 5 | Pages: 772-777

10.1177/15589447251350174 | PMID 40624876 Get It

Background: Kienböck disease most frequently affects 1 wrist and rarely occurs bilaterally. The purpose of this study is to describe the natural history and identify risk factors for development of bilateral Kienböck disease. Methods: After institutional review board approval, 350 patients with surgically managed Kienböck disease from 1976 to 2023 were identified. A retrospective review of the electronic medical record was used to collect demographic, clinical, and radiographic information. Two-tailed student t -test was used for continuous variable, and Fisher’s exact test was used for categorical variables with analysis of power. Results: Ten of 350 patients (2.9%) had bilateral disease. The mean age was 45 (range: 14-62) years, and 6 out of 10 patients were female. The mean follow-up time was 47 (range: 9-274) months. Three of the 10 patients were laborers. Antecedent trauma (n = 2), prior corticosteroid injection (n = 1), and concomitant autoimmune disease (n = 1) were rare events. There was no difference in Lichtman Stage comparing the dominant and nondominant hands, and 72.2% of wrists were ulnar negative. This was higher but not significantly different than the unilateral affected comparison cohort (60%). Sufficient power was demonstrated (0.99). Eighteen of 20 wrists were treated operatively. Two cases required operative revision due to progression of disease. Conclusions: The cause of bilateral versus unilateral Kienböck disease remains unclear. Bilateral disease was not associated with a higher incidence of autoimmune disease, systemic corticosteroid use, or exposure to heavy manual labor. However, thrombosis leading to avascular necrosis of the lunate may be influenced by hypercoagulable and inflammatory diseases. Surgeons should maintain a high index of suspicion for bilateral disease in patients with these comorbidities. Routine screening of the contralateral wrist is unjustified if the patient is asymptomatic.
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study
Kamdar, Manali , Solomon, Scott R. , Arnason, Jon , Johnston, Patrick B., Glaß, Bertram , Bachanová, Veronika , Ibrahimi, Sami , Mielke, Stephan , Mutsaers, Pim , Hernandez‐Ilizaliturri, Francisco J. , Lunning, Matthew A. , Chow, Victor A. , Montheard, Sandrine, Santamaria, Josu, Colicino, Silvia , Stepan, Lara , Izutsu, Koji , Morschhauser, Franck , Colicino, Silvia , Ogasawara, Ken , Abramson, Jeremy S , Bachanova, Veronika , Kamdar, Manali , Mielke, Stephan , Ibrahimi, Sami , Johnston, Patrick B. , Izutsu, Koji , Morschhauser, Franck , Liu, Fei‐Fei , Abramson, Jeremy S.

Mayo Clinic

Journal of Clinical Oncology | July 7, 2025 | Volume: 43 | Issue: 24 | Pages: 2671-2678

10.1200/jco-25-00399 | PMID 40623279 Get It

We report 3-year follow-up results from TRANSFORM comparing lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line primary refractory/early relapsed (≤12 months) large B-cell lymphoma (LBCL). Adults eligible for autologous stem cell transplantation (N = 184) were randomly assigned 1:1 to liso-cel (100 × 10 6 chimeric antigen receptor–positive T cells) or SOC. Results are reported descriptively. With a median follow-up of 33.9 months, median (95% CI) event-free survival was 29.5 months (9.5 to not reached [NR]) for liso-cel versus 2.4 months (2.2 to 4.9) for SOC (hazard ratio [HR], 0.375; 95% CI, 0.259 to 0.542). Median progression-free survival was NR (12.6-NR) for liso-cel versus 6.2 months (4.3-8.6) for SOC (HR, 0.422; 95% CI, 0.279 to 0.639) with 36-month rates of 51% versus 26.5%. Median overall survival (OS) was NR for both arms (HR, 0.757; 95% CI, 0.481 to 1.191), with 66% of patients crossing over to receive liso-cel; 36-month OS rate was 63% for liso-cel versus 52% for SOC. OS HR (0.566 [95% CI, 0.359 to 0.895]) favored liso-cel when accounting for the treatment effect of crossover. Safety results were consistent with previous reports. At 3-year follow-up, liso-cel confirmed superior, more durable efficacy versus SOC with a favorable safety profile and no new safety signals. These data support liso-cel as an effective second-line treatment with curative potential for relapsed/refractory LBCL.
DNA2 protein destruction dictates DNA hyperexcision, cGAS–STING activation, and innate immune response in CDK12-deregulated cancers
Peng, Jiang , Wang, Zhijun , Yan, Binyuan , Zhu, Shouhai , Huang, Zhenlin , Zhang, Jianong , Ding, Donglin , Li, Xiang , Wang, Liguo , Jin, Baiye , Pang, Jun, Xia, Dan , Sun, Rui , Yan, Binyuan , Zhu, Shouhai , Wang, Liguo , Lou, Zhenkun , Jin, Baiye , Huang, Rui , Sun, Rui , Wang, Zhijun, Lou, Zhenkun , Jin, Baiye , Pang, Jun , Huang, Haojie , Sun, Rui

Mayo Clinic

Proceedings of the National Academy of Sciences | July 7, 2025 | Volume: 122 | Issue: 28 | Pages: No page available

10.1073/pnas.2413732122 | PMID 40623188 Get It

CDK12 primarily functions as a transcription regulatory cyclin-dependent kinase (CDK) that controls mRNA elongation, splicing, and polyadenylation. The CDK12 gene is implicated in human cancers since it is frequently mutated and/or deleted in prostate and ovarian cancer but paradoxically amplified in breast cancer. Here, we demonstrate that CDK12 promotes serine-933 phosphorylation of DNA2, a nuclease/helicase critical for replication fork stress regulation, and the phosphorylation subsequently facilitates DNA2 polyubiquitination and degradation mediated by the APC/C CDC20 E3 ubiquitin ligase. CDK12 inactivation induces but amplification suppresses genome-wide expression of interferon response and antigen processing and presentation machinery genes in ovarian and breast cancer cells, respectively. Besides causing aberrant DNA2 stabilization, replication stress, genomic instability, and cytosolic double-stranded DNA (dsDNA) accumulation, CDK12 loss also triggers cGAS–STING activation and innate immune response, which can be reversed by forced expression of replication protein A (RPA) subunits or DNA2 depletion. Our findings identify DNA2 as a phosphorylation substrate of CDK12, connecting CDK12 to cell cycle regulation. These data also reveal DNA2 protein destruction as a critical mechanism that dictates genomic instability, cGAS–STING signaling activation, and innate immune response in CDK12-deregulated cancers.
Exogenous Hormones, Tumor Intrinsic Subtypes, and Breast Cancer
Cornet, Charlotte Le , Truong, Thérèse, Bolla, Manjeet K. , Koutros, Stella, Stone, Jennifer , Shulman, Katerina, Aronson, Kristan J. , Guénel, Pascal, Patel, Alpa V , Bodelón, Clara , Teras, Lauren R., Shahi, Shamim , Dossus, Laure, Kaaks, R., Holleczek, Bernd , Hoppe, Reiner , Czene, Kamila, Hall, P.F., Mannermaa, Arto, Wu, Anna H. , Obi, Nadia , Panayiotidis, Mihalis I. , Haiman, Christopher A., Shu, Xiao , Perou, Charles M. , Alsten, Sarah Van, Eliassen, A. Heather, Kraft, Peter, Ahearn, Thomas U., Evans, D. Gareth , Wolk, Alicja, Easton, Douglas F., Pharoah, Paul D. P., Vachon, Celine M. , Chang-Claude, Jenny, Evans, D Gareth , Perou, Charles M , Stone, Jennifer , Panayiotidis, Mihalis I , Jung, Audrey , Behrens, Sabine , Middha, Pooja , Truong, Thérèse , Jernström, Helena , Wang, Qin , Southey, Melissa C. , Freeman, Laura E. Beane , Koutros, Stella , Rennert, Gad , Murphy, Rachel A. , Guénel, Pascal , Teras, Lauren R. , Lacey, James V. , Dossus, Laure , Kaaks, Rudolf , Brenner, Hermann , Brauch, Hiltrud , Czene, Kamila, Mannermaa, Arto , Michailidou, Kyriaki , McLean, Catriona , Haiman, Christopher A., Augustinsson, Annelie , Zheng, Wei , Troester, Melissa A. , Abubakar, Mustapha , Ahearn, Thomas U., Wolk, Alicja , Milne, Roger L. , Easton, Douglas F. , Schmidt, Marjanka K. , García‐Closas, Montserrat , Vachon, Celine M. , Fortner, Renée T. , Chang‐Claude, Jenny

Mayo Clinic

JAMA Network Open | July 7, 2025 | Volume: 8 | Issue: 7 | Pages: e2519236

10.1001/jamanetworkopen.2025.19236 | PMID 40622713 Get It

ImportanceEtiologic heterogeneity in breast carcinogenesis needs to be well characterized for targeted prevention. Associations between menopausal hormonal therapy (MHT) and oral contraceptive (OC) use and breast cancer intrinsic-like subtypes are not well understood.ObjectiveTo examine whether exogenous hormone use is differentially associated with breast cancer subtypes and to evaluate heterogeneity by intrinsic-like subtypes.Design, Setting, and ParticipantsThis study pooled data from 31 nested and population-based case-control studies involved in the Breast Cancer Association Consortium. The study population included individuals with breast cancer and control participants from 13 case-control studies nested in prospective cohorts (recruited between 1982 and 2011) and 18 population-based case-control studies (recruited between 1990 and 2013). Data analysis was performed in June 2024.ExposureMHT use (estrogen-progestin therapy [EPT] or estrogen-only therapy [ET]) in postmenopausal women and OC use in premenopausal women (never, past use, or current use).Main Outcomes and MeasuresBreast cancer intrinsic-like subtypes (luminal A–like, luminal B–like, luminal B–ERBB2 [formerly HER2 or HER2/neu]-like, ERBB2 enriched–like, or triple-negative) were determined by immunohistochemistry of tumor sections. Polytomous logistic regression was performed to estimate the association between exogenous hormones and risk of breast cancer by intrinsic-like subtypes. Analyses by subtypes were stratified by body mass index (BMI [calculated as weight in kilograms divided by height in meters squared]; healthy weight, 18.5-<25; overweight, 25-<30; or obesity, ≥30).ResultsThis study included 42 269 individuals with breast cancer (11 901 [28.2%] premenopausal and 30 368 [71.8%] postmenopausal; 23 353 [55.2%] had a known intrinsic-like subtype) and 71 072 control participants. The mean (SD) age of all participants was 57.9 (10.9) years. In postmenopausal women, associations between current MHT use (EPT or ET) and breast cancer differed by subtype. Current EPT users with healthy weight were more likely to be diagnosed with luminal A–like (odds ratio [OR], 2.51 [95% CI, 2.26-2.80]) or luminal B–ERBB2-like (OR, 1.95 [95% CI, 1.61-2.37]) subtypes. These associations were attenuated but remained for individuals with overweight (OR, 1.40 [95% CI, 1.02-1.92]) or obesity (OR, 1.68 [95% CI, 1.01-2.78]). EPT use increased the odds of being diagnosed with luminal B–like tumors solely in women with healthy weight (OR, 1.47 [95% CI, 1.17-1.86]). Current ET use was positively associated with luminal A–like disease in women with healthy weight only (OR, 1.16 [95% CI, 1.01-1.32]), showing inverse associations with higher BMI (obesity: OR, 0.65 [95% CI, 0.50-0.85]). In premenopausal women, recent OC use was associated with luminal B–ERBB2-like (OR, 1.50 [95% CI, 1.09-2.08]), ERBB2 enriched–like (OR, 2.33 [95% CI, 1.55-3.51]), and triple-negative (OR, 1.75 [95% CI, 1.33-2.29]; P < .04 for heterogeneity) tumors.Conclusions and RelevanceIn this study, clear differences were observed in associations between current EPT use and luminal-like breast cancer subtypes and other subtypes. EPT users with healthy weight were more likely to be diagnosed with luminal-like breast cancer compared with nonusers. Subtype heterogeneity was less apparent in associations of OC and ET use. Future studies on contemporary formulations, patterns of use, and routes of administration of exogenous hormone usage are warranted.
Efficacy of the Exhalation Delivery System With Fluticasone for Chronic Rhinosinusitis: A Systematic Review and Meta-Analysis
Im, Yeon Hee , Stybayeva, Gulnaz, Hwang, Se Hwan , Hwang, Se Hwan , Stybayeva, Gulnaz

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | July 5, 2025 | Volume: 134 | Issue: 12 | Pages: 907-918

10.1177/00034894251349397 | PMID 40616415 Get It

Objectives: Novel biomechanics of the exhalation delivery system can deliver fluticasone (EDS-FLU; XHANCE) to sinonasal areas above the inferior turbinate, especially sinus drainage pathways not reached by standard nasal sprays. This study aimed to evaluate the effectiveness of EDS-FLU in treating chronic rhinosinusitis (CRS). Methods: Studies were retrieved from PubMed, SCOPUS, Embase, Web of Science, and Cochrane databases up to April 2024. We analyzed 5 studies that compared EDS-FLU with a control group (exhalation delivery system with placebo) on various outcomes, including the 22-item Sinonasal Outcome Test (SNOT-22), nasal symptom scores (congestion, facial pain, olfactory dysfunction, and rhinorrhea), nasal polyp scores, surgical indication rate, and the incidence of adverse effects. Results: Five studies with 2129 patients were included. EDS-FLU significantly improved SNOT-22 score (−20.9657 [−23.5639; −18.3674]) and the polyp score (−1.5099 [−1.7810; −1.2388]) after 6 months. The incidence of epistaxis was significantly higher in the treatment group compared to the control group (OR = 5.7954 [2.1004; 15.9909]). Effects of EDS-FLU on polyp score (−0.6497 [−0.8186; −0.4807]), responder rate (OR = 2.1755 [1.2784; 3.7020]), complete responder rate (OR = 2.0423 [1.0109; 4.1262]), surgical indication rate (OR = 0.7313 [0.5459; 0.9797]), and SNOT-22 score (−6.1513 [−11.3054; −0.9972]) were significantly higher in the treatment group than in the control group. Conclusions: This study demonstrated that EDS-FLU (372 µg twice daily) produced statistically significant improvements compared to EDS-placebo in multiple subjective and objective outcomes, although some adverse effects, such as epistaxis, may occur.
Intraoperative Contrast‐Enhanced Ultrasonography in Pediatric Surgeries: A Review of Techniques, Applications, and Outcomes
Valizadeh, Parya , Rahmani, Saeed , Soltani, Afsaneh, Dehnavi, Ali Zare, Rahmani, Saeed , Ghadimi, Delaram J. , Jannatdoust, Payam , Dehnavi, Ali Zare , Rahmani, Saeed , Samieefar, Noosha

Mayo Clinic

Journal of Clinical Ultrasound | July 4, 2025 | Volume: 53 | Issue: 9 | Pages: 2130-2144

10.1002/jcu.24096 | PMID 40616173 Get It

ABSTRACT Contrast‐enhanced ultrasound (CEUS) utilizes microbubble contrast agents to improve imaging clarity during surgeries, offering real‐time visualization of anatomy and perfusion without ionizing radiation. CEUS has demonstrated feasibility in congenital heart defect repairs for monitoring procedures and cerebral perfusion, in developmental dysplasia of hip surgeries for assessing hip perfusion, in neurosurgery for delineating tumor margins, and in urogenital surgeries for guiding interventions. Intraoperative CEUS improves precision, reduces reliance on postoperative imaging, and enhances safety. While it is a safe and effective tool for intraoperative decision‐making in pediatric surgeries, further studies are needed to expand its applications and standardize its use.
Gene therapy pipelines for osteoarthritis: current innovations, operational challenges, and future directions
Peitso, Valtteri , Ng, Karman , Ellis, R. , Reginster, Jean‐Yves , Evans, Christopher H. , Mobasheri, Ali , Ellis, Ron

Mayo Clinic

Connective Tissue Research | July 4, 2025 | Volume: 66 | Issue: 5 | Pages: 458-465

10.1080/03008207.2025.2520319 | PMID 40611652 Get It

Tumors of the Upper Aerodigestive Tract, Ear, and Jaw
Faquin, William C., Lewis, James S. , Müller, Susan , Wright, John M. , Bishop, Justin A. , Thompson, Lester D.�R.

Mayo Clinic

No container title available | July 4, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.55418/9781933477619 Get It

The head and neck region is a marvel of anatomic complexity and it encompasses a broad array of subsites, each with its own architectural nuances. This histologic richness begets a commensurate diversity of disease. Advances in our understanding of the genetic and epigenetic alterations that underlie many of these tumors have not only refined their classification, but also reshaped our approaches to diagnosis, prognosis, and therapy. This Fascicle reflects these scientific and diagnostic evolutions. Departing from prior editions this volume is organized by anatomic subsite. Each chapter delves into the neoplastic conditions and key differential diagnoses germane to a specific location. This anatomic framework is intended to provide readers with a more practical and intuitive means of navigating the field. This Fascicle serves as a useful companion—equal parts atlas, reference, and diagnostic confidant—for pathologists encountering the intricate, fascinating, and occasionally exasperating world of head and neck pathology.
Review 1: "A Multiplex Mtb-specific FluoroSpot Assay Measuring IFNγ, TNF, and IL2-secreting Cells can Improve Accuracy and Differentiation Across the Tuberculosis Spectrum"
Escalante, Patricio

Mayo Clinic

No container title available | July 3, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1162/2e3983f5.815fb08a Get It

Reviews of "A Multiplex Mtb-specific FluoroSpot Assay Measuring IFNγ, TNF, and IL2-secreting Cells can Improve Accuracy and Differentiation Across the Tuberculosis Spectrum"
Escalante, Patricio , Anonymous, Anonymous

Mayo Clinic

No container title available | July 3, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1162/2e3983f5.e451dbf8 Get It